Tom H Greene

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4170475/publications.pdf

Version: 2024-02-01

441 papers

81,956 citations

108 h-index 421

g-index

276

454 all docs

454 docs citations

454 times ranked

56684 citing authors

#	Article	IF	CITATIONS
1	Which veterans in the Supportive Services for Veteran Families program receive temporary financial assistance and why: a mixed methods study. Journal of Social Distress and the Homeless, 2023, 32, 210-222.	0.9	2
2	Estimating the optimal individualized treatment rule from a costâ€effectiveness perspective. Biometrics, 2022, 78, 337-351.	1.4	5
3	Biased estimation with shared parameter models in the presence of competing dropout mechanisms. Biometrics, 2022, 78, 399-406.	1.4	4
4	Effectiveness of training physical therapists in pain neuroscience education for patients with chronic spine pain: a cluster-randomized trial. Pain, 2022, 163, 852-860.	4.2	5
5	Changes in Pain Catastrophizing and Fear-Avoidance Beliefs as Mediators of Early Physical Therapy on Disability and Pain in Acute Low-Back Pain: A Secondary Analysis of a Clinical Trial. Pain Medicine, 2022, 23, 1127-1137.	1.9	4
6	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology Dialysis Transplantation, 2022, 37, 1647-1656.	0.7	48
7	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
8	Estimation of Black-White Disparities in CKD Outcomes: Comparison Using the 2021 Versus the 2009 CKD-EPI Creatinine Equations. American Journal of Kidney Diseases, 2022, 80, 423-426.	1.9	5
9	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 361-373.	4.5	9
10	Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failureâ€. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008983.	3.9	1
11	Association between unmet medication needs after hospital discharge and readmission or death among acute respiratory failure survivors: the addressing post-intensive care syndrome (APICS-01) multicenter prospective cohort study. Critical Care, 2022, 26, 6.	5.8	8
12	Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open, 2022, 5, e2143001.	5.9	9
13	Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA Network Open, 2022, 5, e2145319.	5.9	24
14	Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2022, 327, 2296.	7.4	113
15	Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors. JAMA Network Open, 2022, 5, e2220680.	5.9	3
16	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.	1.6	85
17	Physical Therapy Referral From Primary Care for Acute Back Pain With Sciatica. Annals of Internal Medicine, 2021, 174, 8-17.	3.9	22
18	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. Annals of the American Thoracic Society, 2021, 18, 590-597.	3.2	28

#	Article	IF	CITATIONS
19	Optimization of Spinal Manipulative Therapy Protocols: A Factorial Randomized Trial Within a Multiphase Optimization Framework. Journal of Pain, 2021, 22, 655-668.	1.4	6
20	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	5 . 2	93
21	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 22-31.	11.4	287
22	Longitudinal Changes in Prorenin and Renin in the Chronic Renal Insufficiency Cohort. American Journal of Nephrology, 2021, 52, 141-151.	3.1	2
23	Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies. Methods in Molecular Biology, 2021, 2249, 281-305.	0.9	0
24	Association of Temporary Financial Assistance With Housing Stability Among US Veterans in the Supportive Services for Veteran Families Program. JAMA Network Open, 2021, 4, e2037047.	5.9	11
25	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	4.5	37
26	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. BMC Nephrology, 2021, 22, 69.	1.8	6
27	A modular approach to integrating multiple data sources into real-time clinical prediction for pediatric diarrhea. ELife, 2021, 10, .	6.0	8
28	Reply to "The Problem of Collinearity in Mental Health and Patient Reported Outcome Research― Journal of Hand Surgery, 2021, 46, e3-e6.	1.6	2
29	Efficacy of LGEâ€MRIâ€guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design. Journal of Cardiovascular Electrophysiology, 2021, 32, 916-924.	1.7	52
30	Heart Failure Hospitalization Risk associated with Iron Status in Veterans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 522-531.	4.5	13
31	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal, 2021, 42, 1216-1227.	2.2	75
32	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	2.7	30
33	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. Journal of the American College of Cardiology, 2021, 77, 1977-1990.	2.8	14
34	Targeting Sedentary Behavior in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 717-726.	4. 5	12
35	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	2.5	17
36	Temporary Financial Assistance Decreased Health Care Costs For Veterans Experiencing Housing Instability. Health Affairs, 2021, 40, 820-828.	5.2	10

#	Article	IF	CITATIONS
37	A New Panel-Estimated GFR, Including \hat{I}^2 2-Microglobulin and \hat{I}^2 -Trace Protein and Not Including Race, Developed in a Diverse Population. American Journal of Kidney Diseases, 2021, 77, 673-683.e1.	1.9	47
38	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	5. 2	182
39	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	1.9	28
40	New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine, 2021, 385, 1737-1749.	27.0	1,236
41	The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. Kidney and Blood Pressure Research, 2021, 46, 768-776.	2.0	2
42	Application of community $\hat{a} \in ``engaged dissemination and implementation science to improve health equity. Preventive Medicine Reports, 2021, 24, 101620.$	1.8	20
43	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 743-754.	11.4	87
44	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 755-766.	11.4	86
45	Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA. Emerging Infectious Diseases, 2021, 27, 2786-2794.	4.3	4
46	High variability in transmission of SARS-CoV-2 within households and implications for control. PLoS ONE, 2021, 16, e0259097.	2.5	11
47	Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ Open, 2021, 11, e055455.	1.9	4
48	Measured and estimated glomerular filtration rate: current status and future directions. Nature Reviews Nephrology, 2020, 16, 51-64.	9.6	166
49	Should You Follow the Betterâ€Hearing Ear for Congenital Cytomegalovirus Infection and Isolated Sensorineural Hearing Loss?. Otolaryngology - Head and Neck Surgery, 2020, 162, 114-120.	1.9	10
50	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104.	1.9	311
51	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c & lt;7%. Circulation, 2020, 141, 407-410.	1.6	95
52	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	6.1	82
53	Clinical predictors for etiology of acute diarrhea in children in resource-limited settings. PLoS Neglected Tropical Diseases, 2020, 14, e0008677.	3.0	17
54	Factors That Contribute to Cost Differences Based on ICU of Admission in Neonates Undergoing Congenital Heart Surgery: A Novel Decomposition Analysis. Pediatric Critical Care Medicine, 2020, 21, e842-e847.	0.5	4

#	Article	IF	CITATIONS
55	Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 1436-1446.	27.0	2,523
56	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	4.5	87
57	Evaluating the association between unmet healthcare needs and subsequent clinical outcomes: protocol for the Addressing Post-Intensive Care Syndrome-01 (APICS-01) multicentre cohort study. BMJ Open, 2020, 10, e040830.	1.9	12
58	Patientâ€reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. Journal of Cardiovascular Electrophysiology, 2020, 31, 3187-3195.	1.7	6
59	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.7	107
60	Comparison of As-Needed and Scheduled Posthospitalization Follow-up for Children Hospitalized for Bronchiolitis. JAMA Pediatrics, 2020, 174, e201937.	6.2	16
61	Improving Care for Patients after Hospitalization with AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2237-2241.	6.1	24
62	Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD). Journal of Cardiac Failure, 2020, 26, 1111.	1.7	0
63	The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes Care, 2020, 43, 1878-1884.	8.6	31
64	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	6.1	106
65	The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC Musculoskeletal Disorders, 2020, 21, 293.	1.9	11
66	Sodium Bicarbonate Supplementation and Urinary TGF- \hat{l}^21 in Nonacidotic Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 200-208.	4.5	20
67	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.7	168
68	Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Internal Medicine, 2020, 180, 552.	5.1	56
69	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American Journal of Kidney Diseases, 2020, 76, 842-850.	1.9	4
70	QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implementation Science, 2020, 15, 9.	6.9	19
71	Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study. Annals of Gastroenterology, 2020, 33, 202-209.	0.6	15
72	Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 2020, 1, 368-375.	2.1	7

#	Article	IF	CITATIONS
73	Propensity score weighting analysis and treatment effect discovery. Statistical Methods in Medical Research, 2019, 28, 2439-2454.	1.5	68
74	PATIENT HEALTH STATUS TRAJECTORIES IN HEART FAILURE WITH RECOVERED EJECTION FRACTION. Journal of the American College of Cardiology, 2019, 73, 970.	2.8	0
75	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	6.1	71
76	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
77	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology: JASN, 2019, 30, 1523-1533.	6.1	41
78	Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. American Journal of Hypertension, 2019, 32, 1170-1177.	2.0	2
79	Mixedâ€effects models for slopeâ€based endpoints in clinical trials of chronic kidney disease. Statistics in Medicine, 2019, 38, 4218-4239.	1.6	32
80	Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, 2019, 74, 267-275.	2.7	16
81	The authors reply. Kidney International, 2019, 96, 520-521.	5.2	0
82	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology: JASN, 2019, 30, 1735-1745.	6.1	163
83	Strengths and limitations of estimated and measured GFR. Nature Reviews Nephrology, 2019, 15, 784-784.	9.6	38
84	An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney International, 2019, 96, 750-760.	5.2	38
85	Ambulatory Management of Childhood Asthma Using a Novel Self-management Application. Pediatrics, 2019, 143, .	2.1	13
86	Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation. European Journal of Vascular and Endovascular Surgery, 2019, 57, 719-728.	1.5	10
87	The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration. Journal of the American Society of Nephrology: JASN, 2019, 30, 890-903.	6.1	38
88	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	27.0	3,760
89	Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis. Annals of Internal Medicine, 2019, 170, 369.	3.9	73
90	Competing Risk Modeling: Time to Put it in Our Standard Analytical Toolbox. Journal of the American Society of Nephrology: JASN, 2019, 30, 2284-2286.	6.1	18

#	Article	IF	Citations
91	Contextual Factors Influencing Implementation of Evidence-Based Care for Children Hospitalized With Asthma. Hospital Pediatrics, 2019, 9, 949-957.	1.3	1
92	Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir. International Journal of Pediatric Otorhinolaryngology, 2019, 118, 124-127.	1.0	28
93	The Familiality of Rapid Renal Decline in Diabetes. Diabetes, 2019, 68, 420-429.	0.6	7
94	Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. JAMA Ophthalmology, 2019, 137, 119.	2.5	3
95	Deceased-donor acute kidney injury is not associated with kidney allograft failure. Kidney International, 2019, 95, 199-209.	5.2	62
96	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.4	199
97	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology, the, 2019, 7, 128-139.	11.4	223
98	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	1.9	49
99	Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. Nephrology Dialysis Transplantation, 2019, 34, 825-833.	0.7	37
100	Evaluating instrument responsiveness in joint function: The HOOS JR, the KOOS JR, and the PROMIS PF CAT. Journal of Orthopaedic Research, 2018, 36, 1178-1184.	2.3	63
101	Impact of Implementing Antibiotic Stewardship Programs in 15 Small Hospitals: A Cluster-Randomized Intervention. Clinical Infectious Diseases, 2018, 67, 525-532.	5.8	58
102	Functional Outcome After Intracranial Presuure Monitoringâ€"Reply. JAMA Pediatrics, 2018, 172, 393.	6.2	0
103	Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 555-563.	11.4	81
104	Extended models for nosocomial infection: parameter estimation and model selection. Mathematical Medicine and Biology, 2018, 35, i29-i49.	1.2	10
105	Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: AÂMulticenter Prospective Cohort Study. American Journal of Kidney Diseases, 2018, 71, 677-689.	1.9	59
106	Benefits and risks of intensive bloodâ€pressure lowering in advanced chronic kidney disease. Journal of Internal Medicine, 2018, 284, 106-107.	6.0	5
107	Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. Diabetes Care, 2018, 41, 775-781.	8.6	43
108	Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. British Journal of Ophthalmology, 2018, 102, 1268-1276.	3.9	70

#	Article	IF	Citations
109	Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. American Journal of Kidney Diseases, 2018, 71, 666-676.	1.9	30
110	Relationship of Sodium Intake and Blood Pressure Varies With Energy Intake. Hypertension, 2018, 71, 858-865.	2.7	42
111	Overcoming Translational Barriers in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1113-1123.	4.5	36
112	A simple method to estimate the time-dependent receiver operating characteristic curve and the area under the curve with right censored data. Statistical Methods in Medical Research, 2018, 27, 2264-2278.	1.5	50
113	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 2018, 137, 134-143.	1.6	134
114	Association between Urine Ammonium and Urine TGF- \hat{l}^21 in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 223-230.	4.5	15
115	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. American Journal of Kidney Diseases, 2018, 71, 91-101.	1.9	57
116	Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970. Clinical Microbiology and Infection, 2018, 24, 110-117.	6.0	16
117	Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria. journal of applied laboratory medicine, The, 2018, 3, 213-221.	1.3	3
118	In Data We Trust? Comparison of Electronic Versus Manual Abstraction of Antimicrobial Prescribing Quality Metrics for Hospitalized Veterans With Pneumonia. Medical Care, 2018, 56, 626-633.	2.4	11
119	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. Journal of the American Heart Association, 2018. 7, e009326.	3.7	79
120	Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 2735-2744.	6.1	103
121	The effectiveness of training physical therapists in pain neuroscience education on patient reported outcomes for patients with chronic spinal pain: a study protocol for a cluster randomized controlled trial. BMC Musculoskeletal Disorders, 2018, 19, 386.	1.9	9
122	Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris. American Journal of Cardiology, 2018, 122, 1809-1816.	1.6	4
123	Health Related Quality of Life in Heart Failure Patients with Improved Ejection Fraction. Journal of Cardiac Failure, 2018, 24, S98.	1.7	0
124	Risk–benefit profile of intensive blood pressure treatment – Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 602.	11.4	0
125	Optimizing treatment protocols for spinal manipulative therapy: study protocol for a randomized trial. Trials, 2018, 19, 306.	1.6	9
126	Biological Variability of Estimated GFR and Albuminuria in CKD. American Journal of Kidney Diseases, 2018, 72, 538-546.	1.9	62

#	Article	IF	CITATIONS
127	Meds to Beds: Improving Patient Care. Journal of Perianesthesia Nursing, 2018, 33, e2-e3.	0.7	o
128	Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control― Circulation, 2018, 137, 2668-2669.	1.6	6
129	Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis. Kidney International, 2017, 91, 746-754.	5.2	78
130	Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With <i>Clostridium difficile</i> Infection. JAMA Internal Medicine, 2017, 177, 546.	5.1	133
131	Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome. Thorax, 2017, 72, 311-317.	5.6	33
132	Associations of Dietary Protein and Energy Intakes With Protein-Energy Wasting Syndrome in Hemodialysis Patients. Kidney International Reports, 2017, 2, 821-830.	0.8	14
133	Variation in Empiric Coverage Versus Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> in Hospitalizations for Community-Onset Pneumonia Across 128 US Veterans Affairs Medical Centers. Infection Control and Hospital Epidemiology, 2017, 38, 937-944.	1.8	21
134	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	6.1	364
135	Cardiac Stress Testing during Workup for Abdominal Aortic Aneurysm Repair Is Not Associated with Improved Patient Outcomes. Annals of Vascular Surgery, 2017, 42, 222-230.	0.9	9
136	Associations of Proteinâ^'Energy Wasting Syndrome Criteria With Body Composition andÂMortality in the General and Moderate Chronic Kidney Disease Populations in the United States. Kidney International Reports, 2017, 2, 390-399.	0.8	22
137	From Static to Dynamic Risk Prediction: Time Is Everything. American Journal of Kidney Diseases, 2017, 69, 492-494.	1.9	10
138	Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2483-2490.	6.1	77
139	Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease. Statistics in Biosciences, 2017, 9, 357-378.	1.2	26
140	Subgroup Selection in Adaptive Signature Designs of Confirmatory Clinical Trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 345-361.	1.0	21
141	Functional Outcome After Intracranial Pressure Monitoring for Children With Severe Traumatic Brain Injury. JAMA Pediatrics, 2017, 171, 965.	6.2	67
142	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. Annals of Internal Medicine, 2017, 167, 375.	3.9	78
143	Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 3005-3013.	6.1	96
144	Understanding patient outcomes after acute respiratory distress syndrome: identifying subtypes of physical, cognitive and mental health outcomes. Thorax, 2017, 72, 1094-1103.	5.6	55

#	Article	IF	Citations
145	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	8.6	68
146	Blood pressure and the risk of chronic kidney disease progression using multistate marginal structural models in the CRIC Study. Statistics in Medicine, 2017, 36, 4167-4181.	1.6	9
147	Association of Maternal Preeclampsia With Infant Risk of Premature Birth and Retinopathy of Prematurity. JAMA Ophthalmology, 2017, 135, 947.	2.5	31
148	Direct concurrent comparison of multiple pediatric acute asthma scoring instruments. Journal of Asthma, 2017, 54, 741-753.	1.7	9
149	Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 953-962.	6.1	203
150	Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodialysis International, 2017, 21, 243-249.	0.9	4
151	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	3.1	194
152	A Dynamic Transmission Model to Evaluate the Effectiveness of Infection Control Strategies. Open Forum Infectious Diseases, 2017, 4, ofw247.	0.9	11
153	Outcomes of Patients With Acute Low Back Pain Stratified by the STarT Back Screening Tool: Secondary Analysis of a Randomized Trial. Physical Therapy, 2017, 97, 330-337.	2.4	9
154	The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis. Clinical Nephrology, 2017, 87, 124-133.	0.7	6
155	Reply to Wolkewitz: When to Use Cumulative Risk-Based Versus Rate-Based Approaches in the Analysis of Hospital-Acquired Infection Risk Factors? That Depends on the Question. Infection Control and Hospital Epidemiology, 2016, 37, 1124-1125.	1.8	0
156	Bone Mineral Density in Navajo Men and Women and Comparison to Non-Hispanic Whites from NHANES (2005â€"2008). Journal of Health Care for the Poor and Underserved, 2016, 27, 644-662.	0.8	1
157	Stewardship in Community Hospitals—Optimizing Outcomes and Resources (SCORE): A Cluster-Randomized Controlled Trial Investigating the Impact of Antibiotic Stewardship in 15 Small, Community Hospitals. Open Forum Infectious Diseases, 2016, 3, .	0.9	4
158	Joint multiple imputation for longitudinal outcomes and clinical events that truncate longitudinal followâ€up. Statistics in Medicine, 2016, 35, 2991-3006.	1.6	10
159	A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811667534.	1.1	39
160	Integrating Time-Varying and Ecological Exposures into Multivariate Analyses of Hospital-Acquired Infection Risk Factors: A Review and Demonstration. Infection Control and Hospital Epidemiology, 2016, 37, 411-419.	1.8	7
161	Neonatal Magnesium Levels Between 24 and 48 Hours of Life and Outcomes for Epilepsy and Motor Impairment in Premature Infants. Pediatric Neurology, 2016, 59, 41-46.	2.1	5
162	Association between Preoperative Vascular Function and Postoperative Arteriovenous Fistula Development. Journal of the American Society of Nephrology: JASN, 2016, 27, 3788-3795.	6.1	56

#	Article	IF	CITATIONS
163	Measuring the Impact of Whole-Body Computed Tomography on Hospital Length of Stay in Blunt Trauma. Academic Radiology, 2016, 23, 582-587.	2.5	5
164	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	1.9	85
165	The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. Nephrology Dialysis Transplantation, 2016, 31, 984-991.	0.7	16
166	Non-GFR Determinants of Low-Molecular-Weight Serum ProteinÂFiltration Markers in CKD. American Journal of Kidney Diseases, 2016, 68, 892-900.	1.9	70
167	Antibiotic Use in Small Community Hospitals. Clinical Infectious Diseases, 2016, 63, 1273-1280.	5.8	46
168	Implementation of a Value-Driven Outcomes Program to Identify High Variability in Clinical Costs and Outcomes and Association With Reduced Cost and Improved Quality. JAMA - Journal of the American Medical Association, 2016, 316, 1061.	7.4	241
169	Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1353-1359.	4.5	17
170	The Associations of Plant Protein Intake With All-Cause Mortality in CKD. American Journal of Kidney Diseases, 2016, 67, 423-430.	1.9	128
171	Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND). Contemporary Clinical Trials, 2016, 47, 1-11.	1.8	35
172	Candidate Surrogate End Points for ESRD after AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 2851-2859.	6.1	47
173	The Effect of Increased Frequency of Hemodialysis on Volume-Related Outcomes: A Secondary Analysis of the Frequent Hemodialysis Network Trials. Blood Purification, 2016, 41, 277-286.	1.8	37
174	Arteriovenous Fistula Development in the First 6 Weeks after Creation. Radiology, 2016, 279, 620-629.	7.3	92
175	Long-Term Effects of Frequent In–Center Hemodialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 1830-1836.	6.1	91
176	GFR Estimation Using \hat{l}^2 -Trace Protein and \hat{l}^2 2-Microglobulin inÂCKD. American Journal of Kidney Diseases, 2016, 67, 40-48.	1.9	121
177	Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study. Journal of the American Society of Nephrology: JASN, 2016, 27, 227-237.	6.1	128
178	Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients. Journal of Dermatological Treatment, 2016, 27, 27-30.	2.2	0
179	Excess Length of Stay Attributable to Clostridium difficile Infection (CDI) in the Acute Care Setting: A Multistate Model. Infection Control and Hospital Epidemiology, 2015, 36, 1024-1030.	1.8	22
180	Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population. Annals of Internal Medicine, 2015, 163, 73-80.	3.9	88

#	Article	IF	Citations
181	Reducing Time-dependent Bias in Estimates of the Attributable Cost of Health Care–associated Methicillin-resistant Staphylococcus aureus Infections. Medical Care, 2015, 53, 827-834.	2.4	35
182	Effect of Naturally Occurring Ozone Air Pollution Episodes on Pulmonary Oxidative Stress and Inflammation. International Journal of Environmental Research and Public Health, 2015, 12, 5061-5075.	2.6	28
183	Net endogenous acid production and mortality in <scp>NHANES III</scp> . Nephrology, 2015, 20, 209-215.	1.6	13
184	Efficient parameter estimation for models of healthcare-associated pathogen transmission in discrete and continuous time. Mathematical Medicine and Biology, 2015, 32, 81-100.	1.2	10
185	Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study. BMC Nephrology, 2015, 16, 87.	1.8	9
186	Comparative Effectiveness of Oral Versus Outpatient Parenteral Antibiotic Therapy for Empyema. Hospital Pediatrics, 2015, 5, 605-612.	1.3	20
187	Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. Hemodialysis International, 2015, 19, 386-401.	0.9	63
188	A dynamic postoperative protocol provides efficient care for pediatric patients with non-ruptured appendicitis. Journal of Pediatric Surgery, 2015, 50, 149-152.	1.6	17
189	The effects of weight change on glomerular filtration rate. Nephrology Dialysis Transplantation, 2015, 30, 1870-1877.	0.7	18
190	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	1.9	41
191	Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients. Blood Purification, 2015, 40, 99-108.	1.8	8
192	Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2578-2587.	6.1	88
193	Light-Intensity Physical Activities and Mortality in the United States General Population and CKD Subpopulation. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1145-1153.	4.5	108
194	Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. American Journal of Kidney Diseases, 2015, 66, 459-468.	1.9	93
195	Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrology Dialysis Transplantation, 2015, 30, 1329-1335.	0.7	6
196	Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006–2010. Clinical Infectious Diseases, 2015, 61, 1403-1410.	5.8	68
197	The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery, 2015, 62, 1258-1265.	1.1	25
198	Epoprostenol Does Not Affect Mortality in Neonates with Congenital Diaphragmatic Hernia. European Journal of Pediatric Surgery, 2015, 25, 454-459.	1.3	15

#	Article	IF	Citations
199	Interstate Variation in Receipt of Nephrologist Care in US Patients Approaching ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1979-1988.	4.5	19
200	Estimating Time to ESRD Using Kidney Failure Risk Equations: Results From the African American Study of Kidney Disease and Hypertension (AASK). American Journal of Kidney Diseases, 2015, 65, 394-402.	1.9	45
201	Variation in pediatric outpatient adenotonsillectomy costs in a multihospital network. Laryngoscope, 2015, 125, 1215-1220.	2.0	30
202	Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 493-503.	6.1	167
203	Randomized Controlled Trials 5: Determining the Sample Size and Power for Clinical Trials and Cohort Studies. Methods in Molecular Biology, 2015, 1281, 225-247.	0.9	22
204	242Stewardship in Community Hospitals–Optimizing Outcomes and Resources (SCORE): A Baseline Analysis of Antimicrobial Use Utilizing CDC NHSN AU Data. Open Forum Infectious Diseases, 2014, 1, S104-S104.	0.9	0
205	Associations of Body Size and Body Composition with Functional Ability and Quality of Life in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1082-1090.	4.5	52
206	Relationships Between the Importation, Transmission, and Nosocomial Infections of Methicillin-Resistant Staphylococcus aureus: An Observational Study of 112 Veterans Affairs Medical Centers. Clinical Infectious Diseases, 2014, 58, 32-39.	5.8	28
207	Risk Factors for Placenta Accreta: A Large Prospective Cohort. American Journal of Perinatology, 2014, 31, 799-804.	1.4	96
208	Quality of Life and Outcomes in African Americans with CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 1849-1855.	6.1	30
209	Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial. Nephrology Dialysis Transplantation, 2014, 29, 168-178.	0.7	45
210	Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study. American Journal of Kidney Diseases, 2014, 64, 867-879.	1.9	59
211	GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials. American Journal of Kidney Diseases, 2014, 64, 848-859.	1.9	109
212	GFR Decline as an End Point for Clinical Trials in CKD: AÂScientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases, 2014, 64, 821-835.	1.9	430
213	Improved hidden Markov model for nosocomial infections. Mathematical Medicine and Biology, 2014, 31, 338-352.	1.2	1
214	Response-based therapy for ruptured appendicitis reduces resource utilization. Journal of Pediatric Surgery, 2014, 49, 1726-1729.	1.6	34
215	A Within-Patient Analysis for Time-Varying Risk Factors of CKD Progression. Journal of the American Society of Nephrology: JASN, 2014, 25, 606-613.	6.1	24
216	Decompressive craniectomy or medical management for refractory intracranial hypertension. Journal of Trauma and Acute Care Surgery, 2014, 76, 944-955.	2.1	32

#	Article	IF	Citations
217	Race/Ethnicity, Age, and Risk of Hospital Admission and Length of Stay during the First Year of Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1402-1409.	4.5	26
218	Association of Kidney Disease Outcomes With Risk Factors forÂCKD: Findings From the Chronic Renal Insufficiency CohortÂ(CRIC) Study. American Journal of Kidney Diseases, 2014, 63, 236-243.	1.9	100
219	Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis. American Journal of Kidney Diseases, 2014, 64, 74-85.	1.9	104
220	Objectives and Design of the Hemodialysis Fistula Maturation Study. American Journal of Kidney Diseases, 2014, 63, 104-112.	1.9	115
221	Atrial Fibrillation Ablation Outcome Is Predicted by Left Atrial Remodeling on MRI. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 23-30.	4.8	316
222	Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. Journal of Human Hypertension, 2014, 28, 18-24.	2.2	59
223	Low-Back Pain Ratings for Lifetime, 1-Month Period, and Point Prevalences in a Large Occupational Population. Human Factors, 2014, 56, 86-97.	3.5	35
224	Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease. Nephrology, 2014, 19, 648-654.	1.6	74
225	Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American Journal of Kidney Diseases. 2014. 63, 244-250.	1.9	55
226	Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: A pilot study. Journal of Pediatric Surgery, 2013, 48, 1348-1356.	1.6	74
227	Low Body Mass Index and Dyslipidemia in Dialysis Patients Linked to Elevated Plasma Fibroblast Growth Factor 23. American Journal of Nephrology, 2013, 37, 183-190.	3.1	25
228	Improved equation for estimating single-pool Kt/V at higher dialysis frequencies. Nephrology Dialysis Transplantation, 2013, 28, 2156-2160.	0.7	41
229	Serum bicarbonate and mortality in adults in NHANES III. Nephrology Dialysis Transplantation, 2013, 28, 1207-1213.	0.7	80
230	Effect of Intensive Blood Pressure Control on Cardiovascular Remodeling in Hypertensive Patients with Nephrosclerosis. International Journal of Nephrology, 2013, 2013, 1-8.	1.3	3
231	A Trial of 2 Strategies to Reduce Nocturnal Blood Pressure in Blacks With Chronic Kidney Disease. Hypertension, 2013, 61, 82-88.	2.7	82
232	Gabapentin Versus Chlordiazepoxide for Outpatient Alcohol Detoxification Treatment. Annals of Pharmacotherapy, 2013, 47, 961-969.	1.9	36
233	Longitudinal Validation of a Tool for Asthma Self-Monitoring. Pediatrics, 2013, 132, e1554-e1561.	2.1	14
234	Facility Size, Race and Ethnicity, and Mortality for In-Center Hemodialysis. Journal of the American Society of Nephrology: JASN, 2013, 24, 2062-2070.	6.1	12

#	Article	IF	Citations
235	Effects of Frequent Hemodialysis on Ventricular Volumes and Left Ventricular Remodeling. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2106-2116.	4.5	70
236	Decreasing Hospital Length of Stay for Bronchiolitis by Using an Observation Unit and Home Oxygen Therapy. JAMA Pediatrics, 2013, 167, 422.	6.2	35
237	The Relationship of Age, Race, and Ethnicity with Survival in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 953-961.	4.5	75
238	Association of Histologic Variants in FSGS Clinical Trial with Presenting Features and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 399-406.	4.5	125
239	Reply to Comment on "Gabapentin Versus Chlordiazepoxide for Outpatient Alcohol Detoxification Treatment― Annals of Pharmacotherapy, 2013, 47, 1743-1743.	1.9	2
240	Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 211-218.	4.5	19
241	Relationship of Left Ventricular Hypertrophy and Diastolic Function With Cardiovascular and Renal Outcomes in African Americans With Hypertensive Chronic Kidney Disease. Hypertension, 2013, 62, 518-525.	2.7	50
242	Associations of Serum Skeletal Alkaline Phosphatase with Elevated C-Reactive Protein and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 26-32.	4.5	36
243	Effect of frequent hemodialysis on residual kidney function. Kidney International, 2013, 83, 949-958.	5.2	186
244	<i>APOL1</i> Risk Variants, Race, and Progression of Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2183-2196.	27.0	654
245	The Associations between Race and Geographic Area and Quality-of-Care Indicators in Patients Approaching ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 610-618.	4.5	49
246	The Balanced Survivor Average Causal Effect. International Journal of Biostatistics, 2013, 9, 291-306.	0.7	4
247	A Weighting Analogue to Pair Matching in Propensity Score Analysis. International Journal of Biostatistics, 2013, 9, 215-34.	0.7	223
248	Determinants of Left Ventricular Mass in Patients on Hemodialysis. Circulation: Cardiovascular Imaging, 2012, 5, 251-261.	2.6	87
249	Relationship between Ambulatory BP and Clinical Outcomes in Patients with Hypertensive CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1770-1776.	4.5	80
250	A Lower Extremity Physical Function Computerized Adaptive Testing Instrument for Orthopaedic Patients. Foot and Ankle International, 2012, 33, 326-335.	2.3	54
251	Pyridorin in Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 131-136.	6.1	130
252	The effect of frequent hemodialysis on nutrition and body composition: Frequent Hemodialysis Network Trial. Kidney International, 2012, 82, 90-99.	5.2	65

#	Article	IF	Citations
253	Racial Differences in Markers of Mineral Metabolism in Advanced Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 640-647.	4.5	30
254	The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients. Nephron Clinical Practice, 2012, 121, c25-c29.	2.3	46
255	New Paradigm for Patient-Reported Outcomes Assessment in Foot & Escarch: Computerized Adaptive Testing. Foot and Ankle International, 2012, 33, 621-626.	2.3	69
256	The Joint Commission Children's Asthma Care Quality Measures and Asthma Readmissions. Pediatrics, 2012, 130, 482-491.	2.1	64
257	High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney International, 2012, 81, 300-306.	5.2	305
258	Agreement in Classifying Bloodstream Infections Among Multiple Reviewers Conducting Surveillance. Clinical Infectious Diseases, 2012, 55, 364-370.	5.8	65
259	Cognitive Function and the Risk of Death in Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 49-57.	3.1	39
260	Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2012, 60, 250-261.	1.9	207
261	Transposon insertion in a cinnamyl alcohol dehydrogenase gene is responsible for a brown midrib1 mutation in maize. Plant Molecular Biology, 2012, 80, 289-297.	3.9	39
262	Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort Study. Journal of the American Society of Hypertension, 2012, 6, 193-200.	2.3	7
263	Quality of life and psychosocial factors in African Americans with hypertensive chronic kidney disease. Translational Research, 2012, 159, 4-11.	5.0	33
264	Associations of Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations With Death and Progression to Maintenance Dialysis in Patients With Advanced Kidney Disease. American Journal of Kidney Diseases, 2012, 60, 567-575.	1.9	65
265	Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrology Dialysis Transplantation, 2012, 27, 990-996.	0.7	37
266	Factors associated with intern noncompliance with the 2003 Accreditation Council for Graduate Medical Education's 30-hour duty period requirement. BMC Medical Education, 2012, 12, 33.	2.4	1
267	Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 2012, 367, 20-29.	27.0	3,072
268	Nonparametric multistate representations of survival and longitudinal data with measurement error. Statistics in Medicine, 2012, 31, 2303-2317.	1.6	5
269	Kidney Function Can Improve in Patients with Hypertensive CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 706-713.	6.1	49
270	Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder. Journal of the American Society of Nephrology: JASN, 2012, 23, 727-738.	6.1	137

#	Article	IF	Citations
271	Longitudinal Progression Trajectory of GFR Among Patients With CKD. American Journal of Kidney Diseases, 2012, 59, 504-512.	1.9	259
272	25-hydroxyvitamin D deficiency is associated with an increased risk of metabolic syndrome in patients with non-diabetic chronic kidney disease. Clinical Nephrology, 2012, 78, 432-441.	0.7	5
273	The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney International, 2011, 80, 1080-1091.	5.2	450
274	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	5.2	609
275	Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2011, 58, 729-736.	1.9	107
276	Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials. Clinical Trials, 2011, 8, 571-580.	1.6	1
277	Evaluation of the PROMIS physical function item bank in orthopaedic patients. Journal of Orthopaedic Research, 2011, 29, 947-953.	2.3	167
278	Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney International, 2011, 79, 356-362.	5.2	179
279	Modeled Urea Distribution Volume and Mortality in the HEMO Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1129-1138.	4.5	15
280	Intradialytic Hypotension and Vascular Access Thrombosis. Journal of the American Society of Nephrology: JASN, 2011, 22, 1526-1533.	6.1	172
281	Equations to Estimate Creatinine Excretion Rate. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 184-191.	4.5	166
282	Use of Aspirin Associates with Longer Primary Patency of Hemodialysis Grafts. Journal of the American Society of Nephrology: JASN, 2011, 22, 773-781.	6.1	42
283	Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrology Dialysis Transplantation, 2011, 26, 848-857.	0.7	22
284	FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. Journal of the American Society of Nephrology: JASN, 2011, 22, 1913-1922.	6.1	411
285	Limitations of Analyses Based on Achieved Blood Pressure. Hypertension, 2011, 57, 1061-1068.	2.7	42
286	Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney International, 2011, 79, 471-477.	5.2	142
287	Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International, 2011, 79, 678-685.	5 . 2	52
288	Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney International, 2011, 79, 228-233.	5.2	55

#	Article	IF	Citations
289	Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease. Kidney International, 2011, 80, 670-678.	5.2	42
290	Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney International, 2011, 80, 868-878.	5.2	208
291	Imprecision of Urinary Iothalamate Clearance as a Gold-Standard Measure of GFR Decreases the Diagnostic Accuracy of Kidney Function Estimating Equations. American Journal of Kidney Diseases, 2010, 56, 39-49.	1.9	115
292	Serum Bicarbonate and Long-term Outcomes in CKD. American Journal of Kidney Diseases, 2010, 56, 907-914.	1.9	110
293	Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/ 1.73 m2. American Journal of Kidney Diseases, 2010, 56, 486-495.	1.9	507
294	Relationship Between Body Mass Index and Proteinuria in Hypertensive Nephrosclerosis: Results From the African American Study of Kidney Disease and Hypertension (AASK) Cohort. American Journal of Kidney Diseases, 2010, 56, 896-906.	1.9	41
295	<i>Insight</i> : Effects of Reduced Intradialytic Urea Generation Rate and Residual Renal Clearance on Modeled Urea Distribution Volume and <i>Kt/V</i> in Conventional, Daily, and Nocturnal Dialysis. Seminars in Dialysis, 2010, 23, 19-24.	1.3	7
296	Updated comorbidity assessments and outcomes in prevalent hemodialysis patients. Hemodialysis International, 2010, 14, 478-485.	0.9	9
297	Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1582-1587.	4.5	70
298	Can Rescaling Dose of Dialysis to Body Surface Area in the HEMO Study Explain the Different Responses to Dose in Women versus Men?. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1628-1636.	4.5	63
299	Malnutrition-Inflammation Modifies the Relationship of Cholesterol with Cardiovascular Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 2131-2142.	6.1	43
300	Rate of ESRD Exceeds Mortality among African Americans with Hypertensive Nephrosclerosis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1361-1369.	6.1	48
301	Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrology Dialysis Transplantation, 2010, 25, 449-457.	0.7	111
302	In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal of Medicine, 2010, 363, 2287-2300.	27.0	898
303	Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney International, 2010, 77, 637-644.	5.2	81
304	Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease. Kidney International, 2010, 77, 1010-1019.	5.2	56
305	Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. New England Journal of Medicine, 2010, 363, 918-929.	27.0	638
306	Validation of a dietary history questionnaire for American Indian and Alaska Native people. Ethnicity and Disease, 2010, 20, 429-36.	2.3	16

#	Article	IF	CITATIONS
307	Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 2482-2488.	0.7	35
308	Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency. New England Journal of Medicine, 2009, 360, 2191-2201.	27.0	265
309	Scaling of Measured Glomerular Filtration Rate in Kidney Donor Candidates by Anthropometric Estimates of Body Surface Area, Body Water, Metabolic Rate, or Liver Size. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1575-1583.	4.5	30
310	Serum Alkaline Phosphatase and Mortality in African Americans with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1805-1810.	4.5	64
311	Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease. Hypertension, 2009, 53, 20-27.	2.7	252
312	Effect of Membrane Permeability on Survival of Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2009, 20, 462-464.	6.1	21
313	Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1115-1120.	4.5	89
314	Usefulness of Adjusting for Clinical Covariates to Improve the Ability of B-Type Natriuretic Peptide to Distinguish Cardiac from Noncardiac Dyspnea. American Journal of Cardiology, 2009, 104, 689-694.	1.6	26
315	Effect of a Very Low-Protein Diet on Outcomes: Long-term Follow-up of the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2009, 53, 208-217.	1.9	210
316	Randomized and Observational Studies in Nephrology: How Strong Is the Evidence?. American Journal of Kidney Diseases, 2009, 53, 377-388.	1.9	32
317	Uric Acid and Long-term Outcomes in CKD. American Journal of Kidney Diseases, 2009, 53, 796-803.	1.9	359
318	Solute Clearances and Fluid Removal in the Frequent Hemodialysis Network Trials. American Journal of Kidney Diseases, 2009, 53, 835-844.	1.9	41
319	Solute-Solver: A Web-Based Tool for Modeling Urea Kinetics for a Broad Range of Hemodialysis Schedules in Multiple Patients. American Journal of Kidney Diseases, 2009, 54, 798-809.	1.9	77
320	Related Causal Frameworks for Surrogate Outcomes. Biometrics, 2009, 65, 530-538.	1.4	152
321	A Semiparametric Joint Model for Longitudinal and Survival Data with Application to Hemodialysis Study. Biometrics, 2009, 65, 737-745.	1.4	17
322	Physical Activity and Mortality in Chronic Kidney Disease (NHANES III). Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1901-1906.	4.5	241
323	A New Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 2009, 150, 604.	3.9	19,025
324	Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney International, 2009, 75, 652-660.	5.2	590

#	Article	IF	CITATIONS
325	Investigating the effects of ties on measures of concordance. Statistics in Medicine, 2008, 27, 4190-4206.	1.6	14
326	Efficient Estimation for Patient-Specific Rates of Disease Progression Using Nonnormal Linear Mixed Models. Biometrics, 2008, 64, 29-38.	1.4	24
327	Varying Coefficients Model with Measurement Error. Biometrics, 2008, 64, 519-526.	1.4	30
328	<i>Dialysis Research</i> : Surfaceâ€Areaâ€Normalized <i>Kt</i> / <i>V</i> : A Method of Rescaling Dialysis Dose to Body Surface Areaâ€"Implications for Differentâ€Size Patients by Gender. Seminars in Dialysis, 2008, 21, 415-421.	1.3	58
329	The Influence of Age on Changes in Healthâ€Related Quality of Life over Three Years in a Cohort Undergoing Hemodialysis. Journal of the American Geriatrics Society, 2008, 56, 1608-1617.	2.6	75
330	Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD. American Journal of Kidney Diseases, 2008, 51, 395-406.	1.9	944
331	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1332-1338.	4.5	61
332	Dosing intermittent haemodialysis in the intensive care unit patient with acute renal failure-estimation of urea removal and evidence for the regional blood flow model. Nephrology Dialysis Transplantation, 2008, 23, 2286-2298.	0.7	14
333	Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrology Dialysis Transplantation, 2008, 23, 1946-1954.	0.7	56
334	Association between Serum \hat{I}^2 2-Microglobulin Level and Infectious Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 69-77.	4.5	86
335	Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis. JAMA - Journal of the American Medical Association, 2008, 299, 2164.	7.4	700
336	Long-term Effects of Renin-Angiotensin System–Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. Archives of Internal Medicine, 2008, 168, 832.	3.8	149
337	An agent-based model for evaluating surveillance methods for catheter-related bloodstream infection. AMIA Annual Symposium proceedings, 2008, , 631-5.	0.2	8
338	Evaluation of the Modification of Diet in Renal Disease Study Equation in a Large Diverse Population. Journal of the American Society of Nephrology: JASN, 2007, 18, 2749-2757.	6.1	498
339	A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrology Dialysis Transplantation, 2007, 23, 52-55.	0.7	4
340	Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. Annals of Internal Medicine, 2007, 147, 19.	3.9	168
341	A Simulation-Based Evaluation of Methods to Estimate the Impact of an Adverse Event on Hospital Length of Stay. Medical Care, 2007, 45, S108-S115.	2.4	25
342	Inflammation and Inverse Associations of Body Mass Index and Serum Creatinine With Mortality in Hemodialysis Patients., 2007, 17, 372-380.		39

#	Article	IF	Citations
343	Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clinical Chemistry, 2007, 53, 766-772.	3.2	1,587
344	Role of Adipose Tissue in Determining Muscle Mass in Patients With Chronic Kidney Disease. , 2007, 17, 314-322.		20
345	Impact of Creatinine Calibration on Performance of GFR Estimating Equations in a Pooled Individual Patient Database. American Journal of Kidney Diseases, 2007, 50, 21-35.	1.9	198
346	Body Mass Index and Mortality in CKD. American Journal of Kidney Diseases, 2007, 50, 404-411.	1.9	61
347	Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. New England Journal of Medicine, 2006, 354, 2473-2483.	27.0	2,528
348	Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate. Annals of Internal Medicine, 2006, 145, 247-254.	3.9	4,606
349	Shared parameter models for the joint analysis of longitudinal data and event times. Statistics in Medicine, 2006, 25, 143-163.	1.6	145
350	Effect of Change in Vascular Access on Patient Mortality in Hemodialysis Patients. American Journal of Kidney Diseases, 2006, 47, 469-477.	1.9	193
351	Quality of Life in the African American Study of Kidney Disease and Hypertension: Effects of Blood Pressure Management. American Journal of Kidney Diseases, 2006, 47, 956-964.	1.9	18
352	Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases, 2006, 48, 739-751.	1.9	133
353	Effect of Dietary Protein Restriction on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2006, 48, 879-888.	1.9	143
354	Relationship Between Homocysteine and Mortality in Chronic Kidney Disease. Circulation, 2006, 113, 1572-1577.	1.6	53
355	Adiponectin and Mortality in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2599-2606.	6.1	254
356	Validation of Creatinine-Based Estimates of GFR When Evaluating Risk Factors in Longitudinal Studies of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2900-2909.	6.1	64
357	Baseline Predictors of Renal Disease Progression in the African American Study of Hypertension and Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2928-2936.	6.1	127
358	Response to Letter Regarding Article, "Relationship Between Homocysteine and Mortality in Chronic Kidney Disease― Circulation, 2006, 114, .	1.6	0
359	Daily Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 33-42.	4.5	161
360	Serum \hat{I}^2 -2 Microglobulin Levels Predict Mortality in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, 546-555.	6.1	393

#	Article	IF	Citations
361	Effect of Dietary Protein Intake on Serum Total CO2 Concentration in Chronic Kidney Disease: Modification of Diet in Renal Disease Study Findings. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 52-57.	4.5	51
362	Surrogate End Points for Clinical Trials of Kidney Disease Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 874-884.	4.5	116
363	Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry, 2006, 52, 5-18.	3.2	1,057
364	The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study. Annals of Internal Medicine, 2005, 142, 342.	3.9	456
365	Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins. Kidney International, 2005, 67, 1539-1546.	5.2	32
366	C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney International, 2005, 68, 766-772.	5.2	329
367	Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study?. Kidney International, 2005, 68, 1766-1776.	5.2	91
368	Performance of the Cockcroft-Gault and Modification of Diet in Renal Disease Equations in Estimating GFR in Ill Hospitalized Patients. American Journal of Kidney Diseases, 2005, 46, 242-252.	1.9	198
369	Relationship of Phosphorus and Calcium-Phosphorus Product With Mortality in CKD. American Journal of Kidney Diseases, 2005, 46, 455-463.	1.9	113
370	Association of Achieved Dialysis Dose with Mortality in the Hemodialysis Study. Journal of the American Society of Nephrology: JASN, 2005, 16, 3371-3380.	6.1	82
371	Low-Level Environmental Lead Exposure and Children's Intellectual Function: An International Pooled Analysis. Environmental Health Perspectives, 2005, 113, 894-899.	6.0	1,750
372	Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial. Clinical Trials, 2005, 2, 400-412.	1.6	29
373	Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials, 2005, 2, 413-422.	1.6	47
374	The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease. Archives of Internal Medicine, 2005, 165, 947.	3.8	264
375	Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations in the Estimation of GFR in Health and in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 459-466.	6.1	599
376	Blood Pressure Control, Drug Therapy, and Kidney Disease. Hypertension, 2005, 46, 44-50.	2.7	34
377	Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 3411-3417.	6.1	51
378	What Did We Learn from the HEMO Study? Implications of Secondary Analyses. , 2005, 149, 69-82.		6

#	Article	IF	CITATIONS
379	The HEMO Study: applicability and generalizability. Nephrology Dialysis Transplantation, 2005, 20, 278-284.	0.7	20
380	Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrology Dialysis Transplantation, 2005, 20, 2765-2774.	0.7	115
381	Dialysis dose as a determinant of adequacy. Seminars in Nephrology, 2005, 25, 76-80.	1.6	8
382	Factors associated with lipoprotein(a) in chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 28-38.	1.9	15
383	Target Blood Pressure and Kidney Disease. Annals of Internal Medicine, 2005, 143, 311.	3.9	2
384	Factors that Affect Postdialysis Rebound in Serum Urea Concentration, Including the Rate of Dialysis: Results from the HEMO Study. Journal of the American Society of Nephrology: JASN, 2004, 15, 194-203.	6.1	70
385	A Comparison of Iothalamate-GFR and Serum Creatinine-Based Outcomes: Acceleration in the Rate of GFR Decline in the African American Study of Kidney Disease and Hypertension. Journal of the American Society of Nephrology: JASN, 2004, 15, 3175-3183.	6.1	69
386	Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney International, 2004, 65, 1386-1394.	5. 2	151
387	The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: Results of the HEMO Study. Kidney International, 2004, 65, 2321-2334.	5. 2	124
388	Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney International, 2004, 66, 355-366.	5.2	157
389	Kinetics of urea and \hat{I}^2 2-microglobulin during and after short hemodialysis treatments. Kidney International, 2004, 66, 1669-1676.	5.2	36
390	Dialyzer Performance in the HEMO Study:In Vivo K O A and True Blood Flow Determined from a Model of Cross-Dialyzer Urea Extraction. ASAIO Journal, 2004, 50, 85-93.	1.6	36
391	Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. American Journal of Kidney Diseases, 2003, 42, 1200-1211.	1.9	87
392	High urine volume and low urine osmolality are risk factors for faster progression of renal disease. American Journal of Kidney Diseases, 2003, 41, 962-971.	1.9	121
393	Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. American Journal of Kidney Diseases, 2003, 42, 44-52.	1.9	157
394	Anthropometrically estimated total body water volumes are larger than modeled urea volume in chronic hemodialysis patients: Effects of age, race, and gender. Kidney International, 2003, 64, 1108-1119.	5.2	72
395	Prescribing an equilibrated intermittent hemodialysis dose in intensive care unit acute renal failure. Kidney International, 2003, 64, 2298-2310.	5.2	32
396	Effects of High-Flux Hemodialysis on Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2003, 14, 3251-3263.	6.1	238

#	Article	IF	Citations
397	Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK). Journal of the American Society of Nephrology: JASN, 2003, 14, S154-S165.	6.1	86
398	The Rationale and Design of the AASK Cohort Study. Journal of the American Society of Nephrology: JASN, 2003, 14, S166-S172.	6.1	97
399	Seasonal Variations in Clinical and Laboratory Variables among Chronic Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 2345-2352.	6.1	98
400	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease <subtitle>Results From the AASK Trial</subtitle> . JAMA - Journal of the American Medical Association, 2002, 288, 2421.	7.4	1,792
401	Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis. New England Journal of Medicine, 2002, 347, 2010-2019.	27.0	1,664
402	Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. American Journal of Kidney Diseases, 2002, 39, 920-929.	1.9	667
403	Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. American Journal of Kidney Diseases, 2002, 40, 932-939.	1.9	36
404	Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney International, 2002, 62, 2208-2215.	5.2	74
405	Mathematical Coupling and the Association Between Kt/V and PCRn. Seminars in Dialysis, 2002, 12, S-20-S-28.	1.3	2
406	Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease. Statistics in Medicine, 2001, 20, 989-1007.	1.6	48
407	A Model for a Proportional Treatment Effect on Disease Progression. Biometrics, 2001, 57, 354-360.	1.4	15
408	Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. American Journal of Kidney Diseases, 2001, 38, 744-753.	1.9	214
409	Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD Study. Kidney International, 2000, 57, 1688-1703.	5.2	335
410	Design and Statistical Issues of the Hemodialysis (HEMO) Study. Contemporary Clinical Trials, 2000, 21, 502-525.	1.9	128
411	Are Observational Studies †Just as Effective' as Randomized Clinical Trials?. Blood Purification, 2000, 18, 317-322.	1.8	19
412	Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO Study. Kidney International, 2000, 58, 2178-2185.	5.2	173
413	Imprecision of the hemodialysis dose when measured directly from urea removal. Kidney International, 1999, 55, 635-647.	5.2	37
414	Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney International, 1999, 56, 1928-1933.	5.2	45

#	Article	IF	CITATIONS
415	Effects of Hemodialyzer Reuse on Clearances of Urea and \hat{I}^2 2-Microglobulin. Journal of the American Society of Nephrology: JASN, 1999, 10, 117-127.	6.1	102
416	Dietary Protein Restriction and the Progression of Chronic Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 2426-2439.	6.1	338
417	Prediction Equation for Glomerular Filtration Rate. Annals of Internal Medicine, 1999, 131, 630.	3.9	0
418	Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney International, 1997, 51, 1908-1919.	5.2	599
419	Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney International, 1997, 51, 2013-2017.	5.2	128
420	Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney International, 1997, 52, 778-791.	5.2	192
421	Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney International, 1997, 52, 1395-1405.	5.2	150
422	Achievement and Safety of a Low Blood Pressure Goal in Chronic Renal Disease. Hypertension, 1997, 29, 641-650.	2.7	186
423	Effects of Blood Pressure Control on Progressive Renal Disease in Blacks and Whites. Hypertension, 1997, 30, 428-435.	2.7	128
424	Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. American Journal of Kidney Diseases, 1996, 27, 652-663.	1.9	300
425	Toxocara canis infection in preschool age children: Risk factors and the cognitive development of preschool children. Neurotoxicology and Teratology, 1996, 18, 167-174.	2.4	39
426	Neonatal Diagnosis of Fetal Alcohol Syndrome: Not Necessarily a Hopeless Prognosis. Alcoholism: Clinical and Experimental Research, 1995, 19, 1550-1557.	2.4	17
427	Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. Annals of Neurology, 1995, 37, 47-54.	5.3	51
428	Effects of brainâ€derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Annals of Neurology, 1995, 37, 505-511.	5.3	131
429	The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Annals of Neurology, 1994, 36, 142-148.	5. 3	131
430	03A Recruitment sampling strategy and power analyses in the MMHD study. Contemporary Clinical Trials, 1994, 15, 33.	1.9	0
431	Serum Lipid Changes Associated With Modified Protein Diets: Results From the Feasibility Phase of the Modification of Diet in Renal Disease Study. American Journal of Kidney Diseases, 1994, 23, 514-523.	1.9	13
432	Dentine lead and intelligence prior to school entry: A statistical sensitivity analysis. Journal of Clinical Epidemiology, 1993, 46, 323-339.	5.0	19

Tom H Greene

#	Article	IF	CITATIONS
433	Contributions of risk factors to elevated blood and dentine lead levels in preschool children. Science of the Total Environment, 1992, 115, 239-260.	8.0	16
434	Covariance pooling and stabilization for classification. Computational Statistics and Data Analysis, 1991, 11, 17-42.	1.2	39
435	Prenatal alcohol exposure and sustained attention in the preschool years. Neurotoxicology and Teratology, 1991, 13, 49-55.	2.4	57
436	Prenatal alcohol exposure and cognitive development in the preschool years. Neurotoxicology and Teratology, 1991, 13, 57-68.	2.4	64
437	Prenatal and preschool age lead exposure: Relationship with size. Neurotoxicology and Teratology, 1991, 13, 417-427.	2.4	52
438	Descriptively sufficient subcollections of flats in matroids. Discrete Mathematics, 1991, 87, 149-161.	0.7	8
439	Prenatal Alcohol Exposure and Preschool Physical Growth: A Longitudinal Analysis. Alcoholism: Clinical and Experimental Research, 1991, 15, 905-913.	2.4	33
440	Prenatal Alcohol Exposure and Language Development. Alcoholism: Clinical and Experimental Research, 1990, 14, 937-945.	2.4	66
441	The depiction of linear association by matroids. Computational Statistics and Data Analysis, 1990, 9, 251-269.	1.2	1